昌吉两次测试早孕试纸昌吉验孕纸一浅一深,昌吉哪个医院打胎水平高,昌吉早孕试纸结果一深一浅,昌吉包皮环切术费用多少,昌吉激光包皮手术疼不疼,昌吉包皮过长会早泄么,昌吉阴茎不能完全勃起什么原因

BAIKONUR, Kazakhstan, Nov. 9 (Xinhua) -- Russia's Phobos-Grunt probe and China's Yinghuo-1 satellite were launched from the Baikonur cosmodrome in Kazakhstan on a Zenit-2SB rocket at 00:16 am Moscow time Wednesday (2016 GMT Tuesday).The main aim of the Phobos-Grunt unmanned mission is to bring back the first ever soil sample from Phobos, the larger of Mars' two moons.Russia had spent about 5 billion rubles (about 161 million U.S. dollars) preparing for the three-year mission, which would include drilling Phobos' surface and returning 200 grams of soil back to Earth, according to Russian state space agency Roscosmos.The mission would also collect bacteria samples for two Russian and one U.S. biological experiments.In the meantime, China's first Mars probe Yinghuo will go into orbit around Mars and observe the planet itself.Phobos-Grunt is planned to reach Mars in 2012, then deploy its lander for Phobos in 2013 and return the soil sample back to Earth in August 2014.The Chinese probe, which would not land on Mars nor return to the Earth, is expected stay permanently in the space and communicate with the ground control directly via satellites.The Chinese probe is 75 cm long, 75 cm wide and 60 cm high. It weighs 115 kilograms and was designed for a two-year life to discover why water disappeared from Mars and shed light on other environmental changes on the planet.Victor Khartov, chief designer and director general of Lavochkin Research & Production Association, told Xinhua that the three-year mission is highly complicated."It consists of eight sub-missions: launch, travel to Mars vicinities, separation with the Chinese probe YH-1, landing on Phobos, soil collection, launch from Phobos, way back to the Earth, and final landing. Failure of any one of them could doom the entire project," he said.The launch of Phobos-Grunt and Yinghuo-1, originally scheduled for October 2009 on a Russian carrier rocket, has been postponed until 2011 due to "technical reasons" on the Russian side.

COPENHAGEN, Nov. 3 (Xinhua) -- The launch of Shenzhou-8 and the successful docking with Tiangong-1 in outer space represented a milestone in both Chinese and international space programs, Danish space scientist and media said Thursday.Michael Linden-Voernle, an astrophysicist at the Tycho Brahe Planetarium in Copenhagen, said new possibilities have opened for both Chinese and international space programs with high expectations."The recent launch of the Tiangong-1 module and now the successful docking with the Shenzhou-8 spacecraft is a very important step - a milestone for the Chinese space program in order to realize the goal of having a permanent presence in space. That means a large space station so this is really an important step, a major milestone," Linden-Voernle told Xinhua in an interview here on Thursday.Besides, a number of Danish news media reported the event, hailing it as a "historic and successful docking." The influential daily Politiken placed a two-minute's video for the successful coupling on its website and showed scenes from the Shenzhou-8 docking with Tiangong-1 together with a short commentary."Tonight two Chinese spacecraft made the historic and successful docking above the atmosphere for the first time ever. China had been the third country in the world after the United States and Russia to master the technique of docking in space. China has laid the foundation for its dominance in space," Politiken said.Jyllands-Posten, one of the bestselling newspapers in Denmark, carried a report with a brief description of China's first space docking under the headline "China closer to its own space station.""As the third country in the world, China has docked two spacecraft together perfectly in space," said Jyllands-Posten.China's unmanned spacecraft Shenzhou-8 and its space lab module Tiangong-1 rendezvoused early Thursday, successfully completing the country's first-ever space docking.

BEIJING, Jan. 05 (Xinhuanet) -- China's satellite television channels have aired fewer entertainment programs this year as broadcasting watchdog's curbs on "excessive entertainment" took effect.The State Administration of Radio, Film and Television has cut two-thirds of "racy" entertainment programs on China's 34 satellite channels since the campaign began, the spokesperson for the administration said on Tuesday.Since the regulation took effect on Jan 1, the total number of entertainment programs scheduled for prime-time -7:30 pm to 10 pm - broadcast a week dropped to 38 from 126 at the end of last year, according to a statement from the administration.Under the regulation, announced in October, each satellite channel can broadcast no more than two entertainment programs a week and the maximum length of the program may not exceed 90 minutes.The targeted programs, including dating shows, reality talent shows and emotional stories on the administration's list, were deemed "excessive entertainment" and showing "less taste"."Satellite channels should design programs with innovative content, promoting traditional virtues and socialist core values in their new entertainment programs," the authority said.The administration considers the move crucial to improving cultural content for the public by offering high-level programs.Meanwhile, the number of news programs on the satellite channels has grown to 193 a day, 33 percent more than in 2011.Currently, news programming on each satellite channel has surpassed two hours, and each channel has at least two 30-minute news programs during prime time.But popular dating shows such as If You Are the One, produced by Jiangsu Satellite TV, and reality shows such as China's Got Talent, aired by Shanghai-based Dragon TV, will remain on during prime time in the weekend.Li Hao, spokesman for Hunan Satellite TV, a broadcaster famous for its entertainment programs, told China Daily the regulation will improve the quality of entertainment programs."We have been exploring how to make entertainment shows more meaningful and valuable," he said, adding that the channel has shortened the length of its two entertainment programs from 110 to 90 minutes."We will supervise programs more strictly, and pay close attention to things such as the clothing and comments of hosts and guests," he added.Cheng Manli, a media professor at Peking University, welcomed the new regulation to limit "less tasteful" programs involving violence and money worship."After all, unhealthy programs may hurt young people who are not able to distinguish right from wrong, which also worries their parents," she said.However, Yu Guoming, a professor at the School of Journalism at Renmin University of China, did not think the regulation was the way to improve cultural development."Whether the entertainment program is good or not should be decided by viewers' reaction, instead of an administration's evaluation," he said. "Residents are under pressure and need to watch shows to relax in our society."Yu also said that a good entertainment program should respect residents' taste and give them more viewing choices, or else it could lead to rigid restrictions.Ma Yuqiang, who runs an online clothing retail company, said the new rule will not affect his daily life, because he can watch the entertainment programs that were taken off prime time on the Internet."I think the regulation will drive most young people to the Internet," Ma, 26, said.

WASHINGTON, Oct. 13 (Xinhua) -- In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study published this week in the Journal of the American Medical Association.The study followed more than 35,533 men 50 or older at 427 sites in the United States, Canada and Puerto Rico. The men were divided into four groups who took daily doses of 400 international units of Vitamin E and 200 micrograms of selenium; Vitamin E and a placebo that looked like selenium; selenium and a placebo that looked like Vitamin E; or two placebos. The recommended daily intake of Vitamin E is about 22.4 international units.The researchers from the Cleveland Clinic found that the rate of prostate cancer detection was greater in all treatment groups when compared with placebo but was statistically significant only in the vitamin E alone group -- a 17 percent increased rate of prostate cancer detection. The difference in rates of prostate cancer between vitamin E and placebo became apparent during the participants' third year in the trial. The elevated risk estimate for vitamin E was consistent across both low- and high-grade disease."The observed 17 percent increase in prostate cancer incidence demonstrates the potential for seemingly innocuous yet biologically active substances such as vitamins to cause harm. The lack of benefit from dietary supplementation with vitamin E or other agents with respect to preventing common health conditions and cancers or improving overall survival, and their potential harm, underscore the need for consumers to be skeptical of health claims for unregulated over-the-counter products in the absence of strong evidence of benefit demonstrated in clinical trials," the researchers said.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.